Squarepoint
CGEM icon

Squarepoint’s Cullinan Oncology CGEM Stock Holding History

Squarepoint’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Buy
+168,117
New +$2.5M ﹤0.01% 1993
2026
Q1 		– Sell
-75,820
Closed -$785K – 4341
2025
Q4 		$785K Sell
75,820
-14,498
-16% -$131K ﹤0.01% 2822
2025
Q3 		$536K Buy
90,318
+75,310
+502% +$552K ﹤0.01% 3180
2025
Q2 		$113K Buy
+15,008
New +$121K ﹤0.01% 4142
2025
Q1 		– Sell
-19,101
Closed -$233K – 4669
2024
Q4 		$233K Sell
19,101
-11,673
-38% -$168K ﹤0.01% 4355
2024
Q3 		$515K Buy
30,774
+20,105
+188% +$357K ﹤0.01% 3068
2024
Q2 		$186K Buy
+10,669
New +$227K ﹤0.01% 3678
2024
Q1 		– Sell
-20,067
Closed -$204K – 4101
2023
Q4 		$204K Buy
+20,067
New +$178K ﹤0.01% 3582
2023
Q2 		– Sell
-15,502
Closed -$159K – 3607
2023
Q1 		$159K Buy
+15,502
New +$171K ﹤0.01% 2871

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Squarepoint's CGEM Position: Q2 2026 in Review

Squarepoint opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 168,117 shares worth $3.06M. The stake represents ﹤0.01% of the portfolio and ranks #1993 among its holdings. This is a return to the name: Squarepoint previously reported a position in CGEM as recently as Q4 2025.

Squarepoint first reported a position in CGEM in Q1 2023 and has held it in 9 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Squarepoint held 168,117 shares of Cullinan Oncology worth $3.06M as of Q2 2026.
  • Cullinan Oncology was a new Squarepoint position in Q2 2026.
  • Cullinan Oncology made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1993 holding.
  • Squarepoint first reported a position in Cullinan Oncology in Q1 2023 and has held it in 9 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.